FDA grants de novo clearance to Powerful Medical's AI for acute heart attack triage
The FDA issued a rare de novo classification to Powerful Medical's AI tool that helps identify severe heart attacks from EKGs during chest-pain emergencies.
The Food and Drug Administration recently granted a de novo classification—a rare regulatory pathway—to an AI model developed by Powerful Medical. The algorithm examines a standard 10-second electrocardiogram to spot ST-segment elevation myocardial infarctions, the most dangerous form of heart attack caused by a total coronary artery blockage. Patients identified by the system can be fast-tracked to a cardiac catheterization laboratory for immediate intervention.
Most AI-based cardiac devices reach the market through the 510(k) clearance route, while de novo clearance, awarded to fewer than ten devices annually, demands stronger clinical evidence. This approval expands the scope of AI in cardiology from preventive screening for arrhythmias and structural issues to real-time emergency decision-making. The move reflects growing confidence in AI’s ability to improve outcomes during acute cardiac events.
Why it matters
The clearance could speed treatment for life-threatening heart attacks, potentially saving lives and demonstrating AI's role in emergency care.
In this story
